Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

Arrowhead Pharmaceuticals, Inc. (ARWR)

Compare

12.20

-0.53

(-4.20%)

At close: April 1 at 4:00:00 PM EDT

12.99

+0.78

+(6.43%)

Pre-Market: 4:20:20 AM EDT

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company

Key Insights Institutions' substantial holdings in Arrowhead Pharmaceuticals implies that they have significant...

Simply Wall St. 7 days ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement-mediated diseases. ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases. The dysregulated activity of the co

Benzinga 22 days ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

PASADENA, Calif., March 10, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025.

Business Wire 22 days ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

PASADENA, Calif., March 06, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compar

Business Wire 26 days ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

PASADENA, Calif., February 28, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We’ll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).

Business Wire last month

ARWR
-4.20%
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

PASADENA, Calif., February 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada.

Business Wire last month

ARWR
-4.20%
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising […]

Insider Monkey last month

ARWR
-4.20%
ARWR: Multiple Catalysts Ahead in 2025…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act (PDUFA) action

Zacks Small Cap Research last month

ARWR
-4.20%
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) First Quarter 2025 Results Key Financial Results Net loss: US$173.1m (loss...

Simply Wall St. last month

ARWR
-4.20%
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

ARWR
-4.20%
SRPT
-2.99%
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...

Despite a challenging quarter, Arrowhead Pharmaceuticals Inc (ARWR) secures a major deal with Sarepta and prepares for potential commercial launches.

GuruFocus.com last month

ARWR
-4.20%
Arrowhead Research: Fiscal Q1 Earnings Snapshot

PASADENA, Calif. AP) — Arrowhead Research Corp. ARWR) on Monday reported a loss of $173.1 million in its fiscal first quarter.

Associated Press Finance last month

ARWR
-4.20%
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

PASADENA, Calif., February 10, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results.

Business Wire last month

ARWR
-4.20%
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

PASADENA, Calif., February 10, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

Business Wire last month

ARWR
-4.20%
Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Guidewire Software Inc. (NYSE: GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE: B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE: APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions.

PR Newswire 2 months ago

APO

APO-PA

ARWR
-4.20%
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

PASADENA, Calif., January 22, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024.

Business Wire 2 months ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif., January 17, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting. Arrowh

Business Wire 2 months ago

ARWR
-4.20%
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for patients living with obesity.

Clinical Trials Arena 3 months ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

PASADENA, Calif., December 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a k

Business Wire 3 months ago

ARWR
-4.20%
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif., December 19, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company’s Board of Directors approved "inducement" grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and

Business Wire 3 months ago

ARWR
-4.20%

Performance Overview

Return	ARWR	S&P 500 (^GSPC)
YTD	-35.08%	-4.23%
1-Year	-56.78%	+7.42%
3-Year	-75.19%	+23.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now

ARWR: Multiple Catalysts Ahead in 2025…

Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Arrowhead Pharmaceuticals Inc (ARWR) Q1 2025 Earnings Call Highlights: Strategic Collaborations ...

Arrowhead Research: Fiscal Q1 Earnings Snapshot

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Performance Overview